Christoph Reichel

Christoph Reichel

Auto-generated profile, based on publicly available information

Christoph Reichel

UCB Pharma Monheim am Rhein Germany

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 September 2023 in Epilepsia
Verified
Journal Article
Open access
LLLieven Lagae
Lieven Lagae
KKKerstin Alexandra Klotz
Kerstin Alexandra Klotz
AFAndrás Fogarasi
András Fogarasi
FFFlorin Floricel
Florin Floricel
CRChristoph Reichel
Christoph Reichel
HKHarriet Kang
Harriet Kang
Objective: This study was undertaken to evaluate the long‐term safety, tolerability, and efficacy of adjunctive brivaracetam (BRV) treatment in pediatric patients with epilepsy.Methods: A phase 3, open‐label, multicenter, long‐term follow‐up trial (N01266; NCT01364597) was conducted on patients (aged 1 month to <17 years at core trial entry; direct enrollers aged 4 to <17 years) treated with BRV. Outcomes included treatment‐emergent adverse events (TEAEs), behavior assessments (Achenbach Child Behavior Checklist [CBCL], Behavior Rating Inventory of Executive Function [BRIEF]/BRIEF‐Preschool version [BRIEF‐P]), and efficacy outcomes (percent change in focal seizure frequency, 50% responder rate for all seizure types for patient subgroups <2 years and ≥2 years of age using daily record card data).Results: Of 257 patients with ≥1 dose of BRV (141 [54.9%] male; mean age = 8.0 years [SD = 4.5]), 36 patients were <2 years of age, and 72.0% of patients had a history of focal seizures. Mean BRV exposure was 3.2 patient‐years. At least one TEAE occurred in 93.4% patients, and 32.3% had serious TEAEs. Seven patients died during the trial; no deaths were considered treatment‐related. Patients ≥2 years of age had a median decrease in 28‐day adjusted focal seizure frequency of 62.9%, and 50.9% had a ≥50% response in all seizures. Patients <2 years of age had a median decrease in 28‐day adjusted focal seizure frequency of 96.9%, and 68.2% had a ≥50% response in all seizures. Kaplan–Meier estimated treatment retention was 72.7%, 64.5%, 57.8%, 53.3%, 50.1%, and 44.8% at 1, 2, 3, 4, 5, and 6 years, respectively. Mean changes (baseline to last evaluation) for all Achenbach CBCL and BRIEF‐P/BRIEF subscale scores were negative, reflecting stability/slight improvement.Significance: Long‐term adjunctive BRV treatment was generally well tolerated and efficacious in reducing seizure frequency, and had high retention rates, with generally stable cognitive/behavioral scores in pediatric patients with epilepsy.

2 October 2024 in Epilepsia Open
Verified
Journal Article
Open access
FFFlorin I. Floricel
Florin I. Floricel
PRPaula E. Reichel
Paula E. Reichel
NDNajla Dickson
Najla Dickson
SFSofia Fleyshman
Sofia Fleyshman
CRChristoph Reichel
Christoph Reichel
JEJan‐Peer Elshoff
Jan‐Peer Elshoff
Objective: The objective of this study is to evaluate possible long‐term effects of treatment with brivaracetam (BRV) on body weight in children with epilepsy.Method: Post hoc analysis of data from patients (aged 1 month to <17 years) with ≥6 months of BRV treatment in a long‐term, open‐label trial (N01266 [NCT01364597]). Outcomes included body weight and body mass index (BMI) over time (z‐score growth curves), and treatment‐emergent adverse events (TEAEs). Previous/ongoing medical conditions that may affect body weight (gastrointestinal and metabolic/nutritional disorders); concomitant antiseizure medications (ASMs) were also evaluated.Results: Two hundred nine patients (mean [standard deviation] age 7.9 [4.6] years) were analyzed. Most (154 [73.7%]) had focal‐onset seizures. At study initiation, median (range) BRV dose was 1.0 (0.4–7.5) mg/kg/day. Overall, 189 (90.4%) patients had a previous or ongoing medical condition (gastrointestinal disorders: 43 [20.6%]; metabolism/nutritional disorders: 26 [12.4%]). Most patients followed z‐score curves for body weight and BMI during BRV treatment, although there were outliers in both directions. Incidences of appetite/weight‐change TEAEs were low. Twenty‐three (11.0%) patients had a TEAE of decreased appetite and 14 (6.7%) had a TEAE of weight decreased.Significance: Long‐term adjunctive BRV was well tolerated in growing children with no indication of detrimental effects on body weight.Plain Language Summary: Brivaracetam is an antiseizure medication (ASM) used to treat seizures in people with epilepsy. Some ASMs can lead to changes in people's appetite and weight. Knowing the effect a drug has on appetite and weight is particularly important in children. We looked at 209 children with epilepsy taking brivaracetam and studied changes in their body weight and body mass index over time. The number of reported side effects related to appetite or weight change was low. There was no apparent long‐term effect on their body weight, even when taking their medical history and use of other ASMs into account.